Lapatinib and letrozole as first-line therapy for metastatic breast cancer: case report of bone metastasis 18 years later

Tumori. 2013 Nov-Dec;99(6):264e-8e. doi: 10.1700/1390.15465.

Abstract

We describe a 63-year-old woman with a diagnosis of breast cancer who relapsed with multiple bone lesions 18 years later. The biological characteristics were estrogen receptor positive, progesterone receptor positive, and HER2-positive cancer. Lapatinib and letrozole was the treatment of choice as a manageable and active first-line therapy for this patient.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / blood*
  • Bone Nails
  • Bone Neoplasms / chemistry
  • Bone Neoplasms / complications
  • Bone Neoplasms / diagnosis
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / secondary*
  • Female
  • Femoral Fractures / prevention & control
  • Humans
  • Ki-67 Antigen / blood
  • Lapatinib
  • Letrozole
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm Staging
  • Nitriles / administration & dosage
  • Pain / etiology
  • Pain Management
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Receptors, Estrogen / blood
  • Receptors, Progesterone / blood
  • Treatment Outcome
  • Triazoles / administration & dosage

Substances

  • Biomarkers, Tumor
  • Ki-67 Antigen
  • Nitriles
  • Quinazolines
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Triazoles
  • Lapatinib
  • Letrozole
  • ERBB2 protein, human
  • Receptor, ErbB-2